“Humans have consumed psychedelics for at least the last 10,000 years. The outlawing of psychedelics in most of the world in the 20th century didn’t stop that, but it did put an end to promising research into their psychotherapeutic applications to treat depression, addiction, PTSD, anxiety, and trauma. Today, we’re in the midst of a psychedelic renaissance, with some psychedelics fast on their way to becoming legal medicines. One of the key players behind this movement is Rick Doblin, Ph.D.. In 01986, he founded the Multidisciplinary Association of Psychedelic Studies (MAPS), a non-profit research and educational organization that has developed the medical and legal framework for the use of psychedelics to treat mental health conditions. MAPS has distributed over $20 million to fund psychedelic research and education, and in 02017 won fast-tracked “Breakthrough Therapy” designation from the FDA for using MDMA-assisted psychotherapy to treat Post-traumatic stress disorder (PTSD). With legalization now in sight, what is the future of psychedelic medicine?”
Tag: Transformation
“Could psychedelics help us heal from trauma and mental illnesses? Researcher Rick Doblin has spent the past three decades investigating this question, and the results are promising. In this fascinating dive into the science of psychedelics, he explains how drugs like LSD, psilocybin and MDMA affect your brain — and shows how, when paired with psychotherapy, they could change the way we treat PTSD, depression, substance abuse and more.”
“Bestselling author Tim Ferriss (Tools of Titans, The 4-Hour Workweek, etc.) probes the science, mysteries, and future of psychedelics with Dr. Roland R. Griffiths, a clinical pharmacologist at Johns Hopkins. Dr. Griffiths has been researching mood-altering compounds for more than 40 years, has published more than 370 scientific papers, and started the psilocybin (think “magic mushrooms”) research program at Johns Hopkins nearly 20 years ago. Dr. Griffiths and his colleagues have been leaders in the re-initiation of research with classic psychedelic drugs, which was blocked for a period of several decades. This session offers details and stories that can help both novices and experienced psychonauts get a better understanding of the applications of these incredible compounds.”
Bruce Sewick
Treating Addictions Using Psychedelic Assisted Therapy
College of DuPage Seminar [2018]
Treating Addictions Using Psychedelic Assisted Therapy
College of DuPage Seminar [2018]
“Recorded as part of a seminar on Psychedelics: Therapy, Culture and Cluster Headaches. Bruce Sewick LCPC, RDDP, CADC discusses the clinical use of psychedelics particularly in the treatment of alcoholics and addicts. Bruce Sewick is an Adjunct instructor in COD’s Human Services and he teaches the Psychedelic Mindview class.”
“Researchers in neuroscience, psychiatry, and clinical practice join other leaders in psychedelic medicine to discuss this rapidly emerging field.”
“A clinical psychologist from Imperial College describes how Magic Mushrooms (Psilocybin), when used in a therapeutic setting, have been found to be a very effective treatment for depression. In this talk she draws on her experiences as working as a therapist on the groundbreaking Psilocybin for Depression study, and introduces us to some of the patients and their stories of transformation. Dr Rosalind Watts completed her clinical psychology training at University College London. After six years of practicing psychotherapy in the NHS, she joined a clinical trial at Imperial College, investigating psilocybin (magic mushrooms) as a treatment for depression. Her research explores patients’ positive views of this intriguing therapy.”
“Research into psychedelic drugs was interrupted in the 1960’s due to regulatory changes. Recently, these compounds are once again studied both as therapeutic agents in psychiatry and as experimental tools to further our understanding of the human brain. David Nutt stands at the forefront of these developments as principal investigator of a team including Robin Carhart-Harris and other researchers at Imperial College, London. Together, they are running clinical trials of psychedelic substances including psilocybin in the treatment of depression. They are also using brain imaging to investigate the effects of psychedelic drugs on activity and connectivity within the brain. At this lecture, he will cover the latest research findings and share his vision of the future of psychedelic science.”
“Dr. Robin Carhart-Harris, the psychologist, neuroscientist and Head of the Psychedelic Research Centre at Imperial College London. Yours is the world’s first organisation dedicated to the research of mind-altering substances and focuses on three key areas of study: mental health, social science and neuroscience. He was the first in the world to investigate the effects of LSD using modern brain imaging, and the first to study psilocybin – the active compound in magic mushrooms – for treating severe depression.”
“Bestselling author Tim Ferriss (Tools of Titans, The 4-Hour Workweek, etc.) probes the science, mysteries, and future of psychedelics with Dr. Roland R. Griffiths, a clinical pharmacologist at Johns Hopkins. Dr. Griffiths has been researching mood-altering compounds for more than 40 years, has published more than 370 scientific papers, and started the psilocybin (think “magic mushrooms”) research program at Johns Hopkins nearly 20 years ago. Dr. Griffiths and his colleagues have been leaders in the re-initiation of research with classic psychedelic drugs, which was blocked for a period of several decades. This session offers details and stories that can help both novices and experienced psychonauts get a better understanding of the applications of these incredible compounds.”